Mutations of the BRAF gene in human cancer
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Cancers arise owing to the accumulation of mutations in critical genes that alter normal programmes of cell proliferation, differentiation and death. As the first stage of a systematic genome-wide screen for these genes, we have prioritized for analysis signalling pathways in which at least one gene is mutated in human cancer. The RAS RAF MEK ERK MAP kinase pathway mediates cellular responses to growth signals. RAS is mutated to an oncogenic form in about 15% of human cancer. The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS. Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers. All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%. Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells. Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation. As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The hotspot BRAF V600E mutation at codon 600 of exon 15 increases the activity of BRAF kinase by 130- to 700-fold [26, 93–95].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [95]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAFV600E mutations occur in ∼10% of colorectal cancer (CRC) patients, leading to poor prognosis.”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAFV600E mutations are present in around 10% of advanced CRC patients and lead to constitutive activation of the MAPK pathway, drug resistance and a poor prognosis [1–4].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BRAF mutations occur in roughly 5–15% of CRCs (1–3, 17)”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [17]
In the citing paper
“Among patients with colorectal cancer, there is an approximately 10% incidence of BRAF mutation [36].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [36]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“There has recently been marked success reported of an inhibitor (STI571) of the BCR-ABL kinase in the treatment of chronic myeloid leukaemi”
BackgroundIdentification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015 · cited 1×
“To evaluate whether activating mutations of BRAF signal through MEK and ERK, we treated cells with the MEK1/2 inhibitor U0126 (ref”
MethodMeaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
Kölch, W. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510289 · Cited by 1,441 · cited 1×
“The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RA”
BackgroundRequirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells
Mulcahy, L. S., Smith, M. R., & Stacey, D. W. (1985) · Nature · doi:10.1038/313241a0 · Cited by 878 · cited 1×
“Studies using injection of the RAS-neutralizing Y13-259 monoclonal antibody have previously shown that most normal cells examined and some tumour cells require RAS function for proliferation in cultur”
MethodThe Raf/MEK/ERK pathway: new concepts of activation
Peyssonnaux, C., & Eychène, A. (2001) · Biology of the Cell · doi:10.1016/s0248-4900(01)01125-x · Cited by 735 · cited 1×
“The RAS–RAF–MEK–ERK–MAP kinase pathway mediates cellular responses to growth signal”
BackgroundIncreasing Complexity of the Ras Signaling Pathway
Vojtek, A. B., & Der, C. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.19925 · Cited by 579
Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation
Mason, C. S. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2137 · Cited by 457 · cited 1×
“Myc-epitope-tagged versions of complementary DNAs containing these mutations were transiently expressed in COS cells, immunoprecipitated using the Myc-tag and examined in a kinase cascade assay using bacterially produced glutathione S -transferase (GST)–MEK, GST–ERK and myelin basic protein (MBP) as sequential substra…”
MethodSelf-citationDifferential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456 · cited 1×
“Myc-epitope-tagged versions of complementary DNAs containing these mutations were transiently expressed in COS cells, immunoprecipitated using the Myc-tag and examined in a kinase cascade assay using bacterially produced glutathione S -transferase (GST)–MEK, GST–ERK and myelin basic protein (MBP) as sequential substra…”
MethodSelf-citationRas Activation of the Raf Kinase: Tyrosine Kinase Recruitment of the MAP Kinase Cascade
Avruch, J. (2001) · Recent Progress in Hormone Research · doi:10.1210/rp.56.1.127 · Cited by 391 · cited 1×
“The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RA”
Background
Cited by
Items 901–1,000 of 1,150
Catalytic Mechanisms and Regulation of Protein Kinases
Wang, Z., & Cole, P. A. (2014) · Methods in Enzymology · doi:10.1016/b978-0-12-397918-6.00001-x · Cited by 177
“B-RAF mutations have been found in 7% of human cancers and in 66% of malignant melanomas, among which the hyperactivating mutation V600E is the predominant form (Davies et al., 2002).”
BackgroundInfluentialThe discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma
Kim, A., & Cohen, M. S. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1201057 · Cited by 169
“As the mutation is demonstrated in approximately 50% of melanomas, this targeted therapy is now able to benefit a larger portion of advanced melanoma patients who in the past were left with limited treatment options [5].”
BackgroundAberrant RNA Splicing in Cancer and Drug Resistance
Wang, B.-D., & Lee, N. (2018) · Cancers · doi:10.3390/cancers10110458 · Cited by 182
“Previous studies have revealed that more than 60% of malignant melanoma patients carry mutations in the BRAF gene, and all mutations are localized within the kinase domain [148].”
BackgroundInfluentialThe hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation
Bedogni, B., Welford, S. M., Cassarino, D. S., Nickoloff, B. J., Giaccia, A. J., & Powell, M. B. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.11.005 · Cited by 179
“These findings are consistent with observations in human melanomas in which inactivation of the CDKN2A locus is quite frequent and where high Akt activity has been associated with development and progression of melanoma and correlated with poor prognosis ( Dai et al., 2005; Stahl et al., 2004).”
ResultMutational spectra of human cancer
Pfeifer, G. P., & Besaratinia, A. (2009) · Human Genetics · doi:10.1007/s00439-009-0657-2 · Cited by 178
“One important discovery was that the BRAF gene, which encodes a serine/threonine kinase in the RAS signaling pathway, harbors somatic mutations in »60% of malignant melanomas (Davies et al. 2002).”
BackgroundBRAF as therapeutic target in melanoma
Wellbrock, C., & Hurlstone, A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.03.019 · Cited by 178
Berres, M., Merad, M., & Allen, C. E. (2015) · British Journal of Haematology · doi:10.1111/bjh.13247 · Cited by 180
“BRAF is a central kinase of the RAS/RAF/MEK pathway, which is essentially involved in numerous cell functions including cell proliferation and migration and is frequently mutated in various cancer cells (Davies et al, 2002).”
BackgroundBuscà, R., Berra, E., Gaggioli, C., Khaled, M., Bille, K., Marchetti, B., Thyss, R., Fitsialos, G., Larribère, L., Bertolotto, C., et al. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200501067 · Cited by 178
“We therefore conclude that the -MSH/cAMP pathway, using MITF as a signal transducer and HIF1 as a target, might contribute to melanoma progression.”
Zell, J. A., Cinar, P., Mobasher, M., Ziogas, A., Meyskens, F. L., & Anton-Culver, H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3604 · Cited by 176
“Gene-environment interactions may explain the observed survival differences in our study (ie, differential mutation spectra in BRAF or NRAS).(36,37) Recently, gene alterations were shown to vary with melanoma site and also with sun exposure levels.”
BackgroundQi Li, W., Kawakami, K., Ruszkiewicz, A., Bennett, G., Moore, J., & Iacopetta, B. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-2 · Cited by 179
P-Rex1 is required for efficient melanoblast migration and melanoma metastasis
Lindsay, C. R., Lawn, S., Campbell, A. D., Faller, W. J., Rambow, F., Mort, R. L., Timpson, P., Li, A., Cammareri, P., Ridgway, R. A., et al. (2011) · Nature Communications · doi:10.1038/ncomms1560 · Cited by 179
“Progression to melanoma is driven primarily by oncogenic mutations of BRAF (50–60%) or NRAS (15–30%”
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression
Oliveira, C., Velho, S., Moutinho, C., Ferreira, A., Preto, A., Domingo, E., Capelinha, A. F., Duval, A., Hamelin, R., Machado, J. C., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1209758 · Cited by 178
“By itself, BRAF V600E mutation shows a 138-fold transforming and oncogenic activity over wild-type BRAF (Davies et al., 2002).”
BackgroundInfluentialSmith, G., Bounds, R., Wolf, H., Steele, R. J. C., Carey, F. A., & Wolf, C. R. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605534 · Cited by 174
“…is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan…”
BackgroundDomingo, E., Niessen, R. C., Oliveira, C., Alhopuro, P., Moutinho, C., Espín, E., Armengol, M., Sijmons, R. H., Kleibeuker, J. H., Seruca, R., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208569 · Cited by 177
“Primer sequences and PCR conditions were based on those reported previously (Davies et al., 2002).”
BackgroundMethodMcArthur, G. A., Puzanov, I., Amaravadi, R., Ribas, A., Chapman, P., Kim, K. B., Sosman, J. A., Lee, R. J., Nolop, K., Flaherty, K. T., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.1938 · Cited by 178
Cicenas, J., Zalyte, E., Bairoch, A., & Gaudet, P. (2018) · Cancers · doi:10.3390/cancers10030063 · Cited by 171
“V600E) [35,36] and is a driver mutation in several cancers, including colorectal cancer [37], melanoma [37], thyroid cancer [38] and non-small cell lung cancer [39].”
BackgroundKondo, Y., Ognjenović, J., Banerjee, S., Karandur, D., Merk, A., Kulhanek, K., Wong, K., Roose, J. P., Subramaniam, S., & Kuriyan, J. (2019) · Science · doi:10.1126/science.aay0543 · Cited by 178
Markham, M. J., Wachter, K., Agarwal, N., Bertagnolli, M. M., Chang, S. M., Dale, W., Diefenbach, C. S. M., Rodriguez-Galindo, C., George, D. J., Gilligan, T. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03141 · Cited by 171
“Approximately 8% to 15% of metastatic colorectal cancers (CRCs) carry the BRAF V600E mutation, which is associated with worse survival and poorer response to standard therapy.(44,45) However, single drugs aimed at inhibiting BRAF have not been effective against BRAF-mutated CRCs.”
BackgroundWeston, C. R., Balmanno, K., Chalmers, C., Hadfield, K., Molton, S. A., Ley, R., Wagner, E. F., & Cook, S. J. (2003) · Oncogene · doi:10.1038/sj.onc.1206261 · Cited by 176
“Two of these pathways are regulated by Ras proteins (Downward, 1998), so it will be interesting to examine the expression of Bim in tumour cell lines with known Ras status and in cells with mutational activation of B-Raf (Davies et al., 2002) or the PI3K pathway (Vasquez and Sellars, 2000).”
BackgroundKinome-wide Decoding of Network-Attacking Mutations Rewiring Cancer Signaling
Creixell, P., Schoof, E. M., Simpson, C. D., Longden, J., Miller, C. J., Lou, H. J., Perryman, L., Cox, T. R., Zivanovic, N., Palmeri, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.056 · Cited by 182
“Serving as a systematic complement to previous efforts identifying the function that individual cancer mutations may play (Davies et al., 2002; Friend et al., 1986; Stehelin et al., 1976), ReKINect is designed to predict the underlying signaling mechanisms and perturbations caused by mutations in cancer, or other comp…”
InfluentialBRAF V600E mutation-specific antibody: A review
Ritterhouse, L. L., & Barletta, J. A. (2015) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2015.02.010 · Cited by 172
“exclusive in many of these tumors, suggesting that they have a similar tumorigenic effect.(1,3,5,6)”
BackgroundDecker, B., Parker, H. G., Dhawan, D., Kwon, E. M., Karlins, E., Davis, B. W., Ramos-Vara, J. A., Bonney, P. L., McNiel, E. A., Knapp, D. W., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0689 · Cited by 174
Mercer, K., Giblett, S., Green, S., Lloyd, D., DaRocha Dias, S., Plumb, M., Marais, R., & Pritchard, C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2211 · Cited by 179
“discovered that oncogenic mutations of the B-RAF gene are present in human cancer samples (5).”
Self-citationCutaneous Photobiology. The Melanocyte vs. the Sun: Who Will Win the Final Round?
Kadekaro, A. L., Kavanagh, R. J., Wakamatsu, K., Ito, S., Pipitone, M. A., & Abdel‐Malek, Z. A. (2003) · Pigment Cell Research · doi:10.1034/j.1600-0749.2003.00088.x · Cited by 180
Begum, S., Rosenbaum, E., Henrique, R., Cohen, Y., Sidransky, D., & Westra, W. H. (2004) · Modern Pathology · doi:10.1038/modpathol.3800198 · Cited by 175
“13 Activating BRAF mutations induce constitutive activation of the signal transduction pathway, providing a potent promitogenic force that drives malignant transformation”
BackgroundAn approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
Xue, Y., Martelotto, L., Baslan, T., Vides, A., Solomon, M., Mai, T. T., Chaudhary, N., Riely, G. J., Li, B. T., Scott, K., et al. (2017) · Nature Medicine · doi:10.1038/nm.4369 · Cited by 174
“BRAF mutations are found in approximately 7% of cancer patients, particularly those with melanoma, colorectal, thyroid or lung cancer 1,2 .”
Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma
Koperek, O., Kornauth, C., Capper, D., Berghoff, A. S., Asari, R., Niederle, B., von Deimling, A., Birner, P., & Preusser, M. (2012) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318246b527 · Cited by 175
“The aberrant BRAF protein causes a constitutive activation of the BRAF serine/threonine kinase and thus leads to an activation of the mitogen-activated protein kinase cascade.(9) BRAF V600E also leads to higher expression of matrix metalloproteases and to increased tumor cell motility.”
BackgroundWNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors
Anastas, J. N., Kulikauskas, R. M., Tamir, T., Rizos, H., Long, G. V., von Euw, E. M., Yang, P.-T., Chen, H.-W., Haydu, L., Toroni, R. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70156 · Cited by 176
“Introduction Over two-thirds of melanomas exhibit activating mutations in the MAPK pathway–activating enzymes NRAS and BRAF, which include BRAFV600E and to a lesser extent BRAFV600K (1, 2).”
A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
Shi, H., Hong, A., Kong, X., Koya, R. C., Song, C., Moriceau, G., Hugo, W., Yu, C. C., Ng, C., Chodon, T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0279 · Cited by 173
Liu, S., & Leach, S. D. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130330 · Cited by 171
Tran, M. A., Gowda, R., Sharma, A., Park, E.-J., Adair, J., Kester, M., Smith, N. B., & Robertson, G. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6614 · Cited by 175
Hoeflich, K. P., Herter, S., Tien, J., Wong, L., Berry, L., Chan, J., O'Brien, C., Modrusan, Z., Seshagiri, S., Lackner, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3563 · Cited by 174
“mutations in BRAF are frequently observed in several tumor types, including malignant melanoma (3) and colorectal carcinoma (4).”
BackgroundChung, K., Yang, S. K., Lee, G. K., Kim, E. Y., Kwon, S., Lee, S. H., Park, D. J., Lee, H. S., Cho, B. Y., Lee, E. S., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02646.x · Cited by 171
Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides
Schirmer, A., Kennedy, J., Murli, S., Reid, R., & Santi, D. V. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600445103 · Cited by 169
The genomic landscape of cutaneous melanoma
Zhang, T., Dutton‐Regester, K., Brown, K. M., & Hayward, N. K. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12459 · Cited by 172
“The discovery of frequent BRAF mutations in melanomas (Davies et al., 2002) and melanocytic nevi (Pollock et al., 2003) provided the initial opportunity to search for genetic differences between tumors arising on skin with or without evidence of chronic sun damage (based on the presence or absence…”
BackgroundChang-Hao Tsao, S., Weiss, J., Hudson, C., Christophi, C., Cebon, J., Behren, A., & Dobrovic, A. (2015) · Scientific Reports · doi:10.1038/srep11198 · Cited by 173
Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease
The Italian Parkinson Genetics Network, Di Fonzo, A., Tassorelli, C., De Mari, M., Chien, H. F., Ferreira, J., Rohé, C. F., Riboldazzi, G., Antonini, A., Albani, G., et al. (2006) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201539 · Cited by 174
Diagnostic and prognostic biomarkers in melanoma.
Weinstein, D. M., Leininger, J., Hamby, C. V., & Safai, B. (2014) · PubMed · Cited by 222
KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases
Zebary, A., Jangard, M., Omholt, K., Ragnarsson-Olding, B., & Hansson, J. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.373 · Cited by 172
Loukopoulos, P., Kanetaka, K., Takamura, M., Shibata, T., Sakamoto, M., & Hirohashi, S. (2004) · Pancreas · doi:10.1097/00006676-200410000-00004 · Cited by 172
“BRAF (v-raf murine sarcoma viral homolog B1) encodes a cytoplasmic serine/threonine kinase that acts in the RAS-RAF-MEK–ERK-MAPK signaling pathway.(25) In agreement with our study, which was mainly composed of K-ras mutant cases (23/25) and in which BRAF mutations were absent, BRAF kinase domain mutations were recentl…”
MethodJi, H., Wang, Z., Perera, S. A., Li, D., Liang, M.-C., Zaghlul, S., McNamara, K., Chen, L., Albert, M., Sun, Y., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4592 · Cited by 174
“Mutations in the BRAF gene were recently identified inf8% of human cancers whereas mutations in ARAF or CRAF seem to be rare if not nonexisting (2, 3).”
BackgroundHyperplastic and Serrated Polyps of the Colorectum
O'Brien, M. J. (2007) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2007.08.007 · Cited by 172
Current systemic therapy for metastatic melanoma
Agarwala, S. S. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.25 · Cited by 173
Melanoma: Molecular Pathogenesis and Therapeutic Management.
Liu, Y., & Sheikh, M. S. (2014) · PubMed · Cited by 212
Mincu, R. I., Mahabadi, A. A., Michel, L., Mrotzek, S. M., Schadendorf, D., Rassaf, T., & Totzeck, M. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.8890 · Cited by 170
Chen, S.-H., Zhang, Y., Van Horn, R. D., Yin, T., Buchanan, S., Yadav, V., Mochalkin, I., Wong, S. S., Yue, Y. G., Huber, L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0896 · Cited by 171
“, G464, G466, and G469) of the kinase domain (1, 10).”
BackgroundRaman-guided subcellular pharmaco-metabolomics for metastatic melanoma cells
Du, J., Su, Y., Qian, C., Yuan, D., Miao, K., Lee, D., Ng, A. H. C., Wijker, R. S., Ribas, A., Levine, R. D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18376-x · Cited by 171
Clinical experience of MEK inhibitors in cancer therapy
Wang, D., Boerner, S. A., Winkler, J. D., & LoRusso, P. M. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.11.009 · Cited by 172
“Most of these BRAF mutations are located in the kinase domain, leading to elevated kinase activity and transforming activity [13].”
BackgroundComputational approaches to identify functional genetic variants in cancer genomes
the International Cancer Genome Consortium Mutation Pathways and Consequences Subgroup of the Bioinformatics Analyses Working Group (2013) · Nature Methods · doi:10.1038/nmeth.2562 · Cited by 171
“The rationale for assessing mutation frequency is that driver mutations provide an adaptive advantage to cancer cells ( Box 1 ; for example, the BRAF V600E substitution found in melanoma 7 ) and should thus be positively selected during the clonal evolution of tumors.”
BackgroundNRAS mutant melanoma: biological behavior and future strategies for therapeutic management
Fedorenko, I. V., Gibney, G. T., & Smalley, K. S. M. (2013) · Oncogene · doi:10.1038/onc.2012.453 · Cited by 167
Trametinib: a MEK inhibitor for management of metastatic melanoma
Rutkowski, P., Lugowska, I., Kosela-Paterczyk, H., & Kozak, K. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s72951 · Cited by 171
“All events 343 (98) 167 (48) 345 (99) 198 (57) 199 (95) 66 (32) 203 (96) 72 (34) Pyrexia 184 (53) 15 (4) 73 (21) 2 (,1) 107 (51) 12 (6) 59 (28) 4 (2) Nausea 121 (35) 1 (,1) 125 (36) 2 (,1) 63 (30) 0 54 (26) 3 (1) Diarrhea 112 (32) 4 (1) 131 (38) 1 (,1) 51 (24) 1 (,1) 30 (14) 2 (,1) Chills 110 (31) 3 (,1) 27 (8) 0 62 (…”
Epigenetic Silencing of Novel Tumor Suppressors in Malignant Melanoma
Muthusamy, V., Duraisamy, S., Bradbury, C. M., Hobbs, C., Curley, D. P., Nelson, B., & Bosenberg, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1274 · Cited by 172
Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
Menzies, A. M., & Long, G. V. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2054 · Cited by 170
“, KIT), resulting in uncontrolled tumor proliferation and survival (1).”
BackgroundSelf-citationFragment Based Drug Design: From Experimental to Computational Approaches
Kumar, A., Voet, A., & Zhang, K. Y. J. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803530467 · Cited by 168
“reported that activating mutations (V600E) in the BRAF encoding gene were present in a significant population of malignant melanoma patients [122].”
BackgroundMelanocytes in development and cancer
Uong, A., & Zon, L. I. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.21935 · Cited by 169
“In the mouse, kit mutants have fewer melanocytes, likely due to a failure in melanoblast migration (Wehrle-Haller and Weston, 1995); in the zebrafish kit mutant (a.k.a sparse), melanocyte specification occurs normally in the embryo; but migration fails and melanocytes undergo apoptosis (Parichy et…”
BackgroundCopper signaling in the brain and beyond
Ackerman, C. M., & Chang, C. J. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.000176 · Cited by 174
“Activating mutations in upstream components of the pathway, such as BRAF, lead to constitutive MAPK signaling, causing tumorigenesis and tumor growth (79).”
BackgroundHigh prevalence of KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malformations
Hong, T., Yan, Y., Li, J., Radovanovic, I., Ma, X., Shao, Y. W., Yu, J., Ma, Y., Zhang, P., Ling, F., et al. (2019) · Brain · doi:10.1093/brain/awy307 · Cited by 169
Mapping Molecular Networks Using Proteomics: A Vision for Patient-Tailored Combination Therapy
Petricoin, E. F., Bichsel, V. E., Calvert, V. S., Espina, V., Winters, M., Young, L., Belluco, C., Trock, B. J., Lippman, M., Fishman, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.509 · Cited by 170
“The discovery and characterization of defective or hyperactive signaling pathways have been a major focus for mechanistic studies of cancer progression, the identification of candidate therapy targets, and the rational selection of patients who are most likely to respond to a therapeutic regimen.(1-19) Gene microarray…”
BackgroundOpportunities and challenges in the development of kinase inhibitor therapy for cancer
Sawyers, C. L. (2003) · Genes & Development · doi:10.1101/gad.1152403 · Cited by 170
“Again, beneficial effects were quickly apparent, because a large fraction of patients had complete or partial remissions (van Oosterom et al. 2001; Demetri et al. 2002).”
BackgroundOncogene-Directed Alterations in Cancer Cell Metabolism
Nagarajan, A., Malvi, P., & Wajapeyee, N. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.06.002 · Cited by 169
“In addition, more than 50% of melanoma and thyroid cancers harbor BRAF mutations, as does a smaller fraction of colorectal and lung cancers [24].”
BackgroundWhole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma
Gartner, J. J., Parker, S. C. J., Prickett, T. D., Dutton-Regester, K., Stitzel, M. L., Lin, J. C., Davis, S., Simhadri, V. L., Jha, S., Katagiri, N., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304227110 · Cited by 168
“Recurrent nonsynonymous mutations, including v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E and transformation/transcription domain-associated protein (TRRAP) S722F substitutions, were found (1, 13) as well as 16 recurrent synonymous mutations (Table 1).”
Obesity and colorectal cancer: molecular features of adipose tissue
Martinez-Useros, J., & Garcia-Foncillas, J. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0772-5 · Cited by 167
“Oncogenic mutations of RAS (including NRAS and KRAS) and BRAF, which activate the MAPK signaling pathway, occur in 37 and 13 % of colorectal cancers, respectively [118–120].”
BackgroundEGFR TKI combination with immunotherapy in non-small cell lung cancer
Ahn, M.-J., Sun, J.-M., Lee, S.-H., Ahn, J. S., & Park, K. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1300656 · Cited by 169
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Leonetti, A., Facchinetti, F., Rossi, G., Minari, R., Conti, A., Friboulet, L., Tiseo, M., & Planchard, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.006 · Cited by 168
Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma
Hu, X., Fujimoto, J., Ying, L., Fukuoka, J., Ashizawa, K., Sun, W., Reuben, A., Chow, C.-W., McGranahan, N., Chen, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10877-8 · Cited by 173
Self-citationHalilovic, E., She, Q.-B., Ye, Q., Pagliarini, R., Sellers, W. R., Solit, D. B., & Rosen, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0409 · Cited by 168
mTOR Is Activated in the Majority of Malignant Melanomas
Karbowniczek, M., Spittle, C. S., Morrison, T., Wu, H., & Henske, E. P. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701074 · Cited by 168
Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks
Śmiech, M., Leszczyński, P., Kono, H., Wardell, C., & Taniguchi, H. (2020) · Genes · doi:10.3390/genes11111342 · Cited by 168
“In particular, the accumulation of pathological changes in the proto-oncogenes leads to significant cellular defects [24].”
BackgroundResistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options
Villanueva, J., Vultur, A., & Herlyn, M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1243 · Cited by 168
“Early efforts were focused on the development of mutant BRAF inhibitors due to the presence of BRAF mutations in 50% of melanomas (5).”
BackgroundGeldanamycin and its anti-cancer activities
Fukuyo, Y., Hunt, C. R., & Horikoshi, N. (2010) · Cancer Letters · doi:10.1016/j.canlet.2009.07.010 · Cited by 167
Scolyer, R. A., Long, G. V., & Thompson, J. F. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.03.002 · Cited by 169
“Aberrant activation of the mitogen-activated protein kinase (MAPK) pathway is present in over 80% of primarymelanomas (Curtin et al., 2006, 2005; Davies et al., 2002; Garrido and Bastian, 2010; Long et al., in press; Platz et al., 2008; Van Raamsdonk et al., 2009; Van Raamsdonk et al., 2010), and…”
BackgroundLack of BRAF mutations in uveal melanoma.
Rimoldi, D., Salvi, S., Líénard, D., Lejeune, F. J., Speiser, D. E., Zografos, L., & Cerottini, J. (2003) · PubMed · Cited by 169
Sebolt-Leopold, J. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0333 · Cited by 167
Mittapalli, R. K., Vaidhyanathan, S., Sane, R., & Elmquist, W. F. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.192195 · Cited by 167
“Among the BRAF mutations approximately 80% exhibit a valine-to-glutamic acid substitution (V600E; BRAF), resulting in constitutive expression of kinase activity (Davies et al., 2002).”
BackgroundColorectal Cancer: Molecular Mutations and Polymorphisms
Sameer, A. S. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00114 · Cited by 171
“The mutation V600E confers transformant activity to the cells because it mimics the phosphorylation of T599 and/or S602 in the AS and so Braf rests constitutively active in a RAS independent manner (Wan et al., 2004).”
BackgroundActivating MET kinase rearrangements in melanoma and Spitz tumours
Yeh, I., Botton, T., Talevich, E., Shain, A. H., Sparatta, A. J., de la Fouchardiere, A., Mully, T. W., North, J. P., Garrido, M. C., Gagnon, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms8174 · Cited by 167
Antisense therapy for cancer—the time of truth
Jansen, B., & Zangemeister-Wittke, U. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00903-8 · Cited by 168
Translating cancer genomes and transcriptomes for precision oncology
Roychowdhury, S., & Chinnaiyan, A. M. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21329 · Cited by 168
The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
Watson, I. R., Li, L., Cabeceiras, P. K., Mahdavi, M., Gutschner, T., Genovese, G., Wang, G., Fang, Z., Tepper, J. M., Stemke-Hale, K., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1232-t · Cited by 169
“The identification of oncogenic mutations in BRAF, predominantly at codon 600 (2), was the main driving force in the development of small molecule inhibitors targeting MAPK kinase kinases (MEK) and BRAF in melanoma, which includes vemurafenib and dabrafenib.”
Analysis of the genome to personalize therapy for melanoma
Davies, M. A., & Samuels, Y. (2010) · Oncogene · doi:10.1038/onc.2010.323 · Cited by 165
“Recently, a number of studies have demonstrated that BRAF inhibitors, including PLX4032, activate MEK and MAPK in melanoma cell lines with wild-type BRAF, including cell lines with mutant NRAS (Halaban et al., 2010; Hatzivassiliou et al., 2010; Heidorn et al., 2010).”
InfluentialThe BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms
Arcaini, L., Zibellini, S., Boveri, E., Riboni, R., Rattotti, S., Varettoni, M., Guerrera, M. L., Lucioni, M., Tenore, A., Merli, M., et al. (2012) · Blood · doi:10.1182/blood-2011-08-368209 · Cited by 167
Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies
Bikker, J. A., Brooijmans, N., Wissner, A., & Mansour, T. S. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8010542 · Cited by 166
Schirripa, M., Cremolini, C., Loupakis, F., Morvillo, M., Bergamo, F., Zoratto, F., Salvatore, L., Antoniotti, C., Marmorino, F., Sensi, E., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.28955 · Cited by 166
“Liver only Yes 93 (35) 116 (32) 16 (36) 20 (29) 0.”
PCR-amplification of GC-rich regions: 'slowdown PCR'
Frey, U. H., Bachmann, H. S., Peters, J., & Siffert, W. (2008) · Nature Protocols · doi:10.1038/nprot.2008.112 · Cited by 165
“Proof of principle To confirm the usefulness of our protocol, we chose exon1 of the BRAF gene, which had escaped amplification and sequencing despite the use of five different primer pair”
MethodA brief history of melanoma: from mummies to mutations
Rebecca, V. W., Sondak, V. K., & Smalley, K. S. M. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e328351fa4d · Cited by 163
The Role of Altered Cell–Cell Communication in Melanoma Progression
Haass, N. K., Smalley, K. S. M., & Herlyn, M. (2004) · Journal of Molecular Histology · doi:10.1023/b:hijo.0000032362.35354.bb · Cited by 170
B-Raf V600E and thrombospondin-1 promote thyroid cancer progression
Nucera, C., Porrello, A., Antonello, Z. A., Mekel, M., Nehs, M. A., Giordano, T. J., Gerald, D., Benjamin, L. E., Priolo, C., Puxeddu, E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004934107 · Cited by 168
Falchook, G. S., Trent, J. C., Heinrich, M. C., Beadling, C., Patterson, J., Bastida, C. C., Blackman, S. C., & Kurzrock, R. (2013) · Oncotarget · doi:10.18632/oncotarget.864 · Cited by 169
“The most common BRAF mutation is a substitution of valine with glutamic acid at amino acid position 600 (V600E), which locks BRAF into its active conformation, resulting in a ten-fold increase in activity over wild-type BRAF[17].”
BackgroundMachine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas
Way, G. P., Sanchez-Vega, F., La, K., Armenia, J., Chatila, W. K., Luna, A., Sander, C., Cherniack, A. D., Mina, M., Ciriello, G., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.046 · Cited by 165
“First, we examined mutation status for BRAF, a well-characterized oncogene downstream of Ras genes (Davies et al., 2002).”
The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells
Panka, D. J., Wang, W., Atkins, M. B., & Mier, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0808 · Cited by 167
“(1), whereas the A375 line is homozygous as determined by sequence”
BackgroundRetractedHornberg, J. J., Bruggeman, F. J., Binder, B., Geest, C. R., de Vaate, A. J. M. B., Lankelma, J., Heinrich, R., & Westerhoff, H. V. (2005) · The FEBS Journal · doi:10.1111/j.1432-1033.2004.04404.x · Cited by 166
Lee, J. T., Li, L., Brafford, P. A., van den Eijnden, M., Halloran, M. B., Sproesser, K., Haass, N. K., Smalley, K. S. M., Tsai, J., Bollag, G., et al. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00763.x · Cited by 166
“Since the identification of a highly prevalent somatic mutation (V600E) of the BRAF gene in 2002 (Davies et al., 2002), several inhibitors of the Raf ⁄ MEK ⁄ ERK signal transduction cascade have been developed (Shepherd et al.”
BackgroundIQGAP1 modulates activation of B-Raf
Ren, J.-G., Li, Z., & Sacks, D. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611308104 · Cited by 168
Landa, I., Ruiz-Llorente, S., Montero-Conde, C., Inglada-Pérez, L., Schiavi, F., Leskelä, S., Pita, G., Milne, R., Maravall, J., Ramos, I., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000637 · Cited by 164
“genetic alterations involving the RET/PTC-RAS-BRAF signalling pathway have been described as causal somatic changes in PTC and FTC [4–9].”
BackgroundShinozaki, M., O'Day, S. J., Kitago, M., Amersi, F., Kuo, C., Kim, J., Wang, H.-J., & Hoon, D. S. B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2120 · Cited by 164
Ipilimumab for Patients With Advanced Mucosal Melanoma
Postow, M. A., Luke, J. J., Bluth, M. J., Ramaiya, N., Panageas, K. S., Lawrence, D. P., Ibrahim, N., Flaherty, K. T., Sullivan, R. J., Ott, P. A., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0464 · Cited by 166
Loughrey, M. B., Waring, P. M., Tan, A., Trivett, M., Kovalenko, S., Beshay, V., Young, M.-A., McArthur, G., Boussioutas, A., & Dobrovic, A. (2007) · Familial Cancer · doi:10.1007/s10689-007-9124-1 · Cited by 165
“Following the identification of somatic BRAF mutations in a subset of CRC, it was recognised that these mutations were mostly associated with tumours displaying MSI [24, 25].”
BackgroundInfluentialKnight, T., & Irving, J. A. E. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00160 · Cited by 164
“About two-thirds of melanoma patients have BRAF mutations (44).”
BackgroundPacheco-Pinedo, E. C., Durham, A. C., Stewart, K. M., Goss, A. M., Lu, M. M., DeMayo, F. J., & Morrisey, E. E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44871 · Cited by 164
Ikenoue, T., Hikiba, Y., Kanai, F., Tanaka, Y., Imamura, J., Imamura, T., Ohta, M., Ijichi, H., Tateishi, K., Kawakami, T., et al. (2003) · PubMed · Cited by 164
Metadata
- Authors
- Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W. C., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., & Futreal, P. A.
- Affiliations
- Wellcome Sanger Institute (GB)
- Institute of Cancer Research (GB)
- Western Infirmary (GB)
- University of York (GB)
- Duke University (US)
- National Research Council (IT)
- University of Sassari (IT)
- Royal Brompton Hospital (GB)
- Queen Mary Hospital (CN)
- Abramson Cancer Center (US)
- Corresponding author
- Wooster, Richard
- ORCID
- Davies, Helen
- Edkins, Sarah
- Teague, Jon
- Garnett, Mathew J.
- Dicks, Ed
- Gray, Kristian
- Hughes, Jaime
- Kosmidou, Vivian
- Menzies, Andrew
- Watt, Stephen
- Hooper, Steven
- Shipley, Janet
- Hargrave, Darren
- Maitland, Norman
- Riggins, Gregory J.
- Bigner, Darell D.
- Palmieri, Giuseppe
- Cossu, Antonio
- Flanagan, Adrienne
- Nicholson, Andrew
- Ho, Judy W. C.
- Yuen, Siu T.
- Paterson, Hugh
- Marais, Richard
- Stratton, Michael R.
- Futreal, P. Andrew
- Venue
- Nature
- Published
- 2002-06
- Volume
- 417
- Issue
- 6892
- Pages
- 949-954
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2163188200
- Cited by
- 10,674
- References
- 24
- Citations by year
- 2026: 221 · 2025: 282 · 2024: 435 · 2023: 450 · 2022: 442 · 2021: 506 · 2020: 538 · 2019: 482 · 2018: 519 · 2017: 576 · 2016: 576 · 2015: 649 · 2014: 701 · 2013: 688 · 2012: 563
- FWCI
- 87.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- BRAF mutation, somatic missense mutations, melanoma, oncogenic Ras, kinase activity, malignant transformation, therapeutic target
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Cell Division, Cell Transformation, Neoplastic, DNA Mutational Analysis, Enzyme Activation, Humans, Melanoma, Molecular Sequence Data, Neoplasms, Tumor Cells, Cultured, 3T3 Cells, Protein Structure, Tertiary, ras Proteins, Proto-Oncogene Proteins c-raf, Mutation, Missense, Mitogen-Activated Protein Kinases, MAP Kinase Signaling System, Proto-Oncogene Proteins B-raf, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.